Fig. 7: Simultaneous expression of FOXM1 and DKK1 is associated with poor prognosis of ESCC cases.

A and C ESCC tissues (n = 82) were stained with anti-DKK1 or anti-FOXM1 antibody and hematoxylin. Black boxes show enlarged images. Numbers of DKK1- and/or FOXM1-positive (high or low expression) cases are shown in the right panels (A). B Percentage of FOXM1 high expressing, low expressing, and negative cases in the DKK1 high expressing and negative cases. D The relationship between relapse-free survival or overall survival and co-expression of DKK1 and FOXM1 in ESCC patients was analyzed (n = 82). Tumors in which positive staining for DKK1 and FOXM1 covered >5% of the total area were classified as DKK1 (+) / FOXM1(+) (n = 40; 48.8%). *P < 0.05 (Pearson’s chi-square test); Scale bars, 100 µm (A and C). The data were analyzed using Kaplan–Meier survival curves, and the Generalized Wilcoxon test was used for statistical analysis (D).